New label approved to reflect Thrombin-JMI manufacturing changes

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.

Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.

Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.

Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.

The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.

The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.